Amicus buys Callidus for $15mm in stock plus up to $115mm in earn-outs
Executive Summary
Amicus Therapeutics Inc. (lysosomal storage disorders) acquired closely held Callidus Biopharma Inc., which is developing enzyme replacement therapies for LSDs. Callidus will receive $15mm worth of Amicus common stock--7.2mm shares at $2.08 each.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice